Market Research Logo

COPD Drugs Market in China 2016-2020

About the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China

Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get worse and damages the lungs. The disease cannot be cured, and can only be managed and treated.The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly 10% of the population in the region who are over the age of 40 years has COPD. The disease is expected to become one of the leading causes of death in the country by 2020. Lack of awareness about the disease and its treatment options affects the growth of the market in this region.

Technavio’s analysts forecast the chronic obstructive pulmonary disease drugs market in China to grow at a CAGR of 15.56% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the chronic obstructive pulmonary disease drugs market in China for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the total consumption of the chronic obstructive pulmonary disease drugs globally. The report does not include revenue generated from the aftermarket service of the product.

The market is divided into the following segments based on drug class:

  • Bronchodilators
  • Phosphodiesterase-4 (PDE-4) inhibitors
  • Steroids
  • Combination therapies
Technavio's report, Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca
  • Boehringer Ingelheim
  • GSK
  • Merck
  • Novartis
Other prominent vendors
  • Ache Laboratorios Farmaceuticos
  • Almirall
  • Aquinox Pharmaceuticals
  • Ario Pharma
  • BioMarck Pharmaceuticals
  • Gilead Sciences
  • Mereo BioPharma Group
  • Mylan
  • Orion
  • Pearl Therapeutics
  • Prosonix
  • Teva Pharmaceutical Industry
  • Theravance Biopharma
  • Theron Pharmaceuticals
  • Verona Pharma
  • Xention
  • ZAI Lab
Market driver
  • Increase in environmental pollution
  • For a full, detailed list, view our report
Market challenge
  • Low diagnosis rate
  • For a full, detailed list, view our report
Market trend
  • Increased focus on combination therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – COPD Drugs Market in China 2016-2020

Technavio recognizes the following companies as the key players in the COPD drugs market in China: AstraZeneca, Boehringer Ingelheim, GSK, Merck, and Novartis.

Other Prominent Vendors in the market are: Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, BioMarck Pharmaceuticals, Gilead Sciences, Mereo BioPharma Group, Mylan, Orion, Pearl Therapeutics, Prosonix, Teva Pharmaceutical Industry, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention, and ZAI Lab.

Commenting on the report, an analyst from Technavio’s team said: “A key trend which is boosting market growth is the increased focus on combination therapies. Combination therapies have a better advantage over monotherapies in providing better efficacy in the treatment of a condition. Manufacturers are now concentrating on developing combination therapies to treat COPD.These combination therapies reduce COPD-related hospitalizations and bring out better treatment outcomes in patients. Thus, the development of combinations therapies will increase the patient compliance toward the uptake of medications and help in the growth of the market.”

According to the report, pollutants such as ground-level ozone, carbon dioxide, smog, fumes from vehicles, and particulates such as dust, soot, and pollen grains are known to trigger diseases such as COPD, asthma, bronchitis, and other respiratory issues. Airborne particles, sulfur dioxide, and nitrogen oxide are critical environment pollutants that worsen respiratory symptoms. Rapid globalization, urbanization, and industrialization have led to the rise in environmental pollution, which has increased the prevalence of COPD.

Further, the report states that a major factor that could hamper market growth is the low diagnosis rate of COPD. It is difficult for physicians to recognize COPD at an early stage as the first symptoms of the disease include common problems such as a cough, sputum production, and shortness of breath. Thus, the diagnosis rate is only about one-third of the prevalent cases. This low diagnosis of COPD can be attributed to the lack of physician’s awareness about the risk factors, symptoms, and biomarkers of the disease.



Companies Mentioned

AstraZeneca, Boehringer Ingelheim, GSK, Merck, Novartis, Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, BioMarck Pharmaceuticals, Gilead Sciences, Mereo BioPharma Group, Mylan, Orion, Pearl Therapeutics, Prosonix, Teva Pharmaceutical Industry, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention, and ZAI Lab.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • COPD: An overview
    • Causes and risk factors
    • Symptoms
    • Diagnosis
    • Management
  • China-Country snapshot
    • Social and economic conditions
      • Table China GDP 2010-2014 ($ trillions)
      • Table Healthcare expenditure 2009-2013 (% of GDP)
    • Healthcare reform
      • Table Healthcare reforms in China
    • Healthcare infrastructure
  • Pharmaceutical industry in China
    • Market overview
      • Table Pharmaceutical market in China 2015-2020 ($ billions)
    • Major pharmaceutical vendors in China
      • Table Some top domestic and international vendors operating in China
      • Table China pharmaceutical market overview: SWOT analysis
    • Opportunities for global and local vendors
    • Drug approval process in China
      • Table New drug approval (NDA) review process in China
      • Table New drug approval process in China
      • Table Drug registration classification and requirements in China
  • Drug pricing and reimbursement
    • Market-driven drug pricing strategy
      • Table Changes in drug pricing system before and after 2015 reforms
    • Scrutinization of illegal pricing of drugs
  • Pipeline portfolio
    • Table Pipeline portfolio: COPD drugs
  • Global respiratory drugs market
    • Market overview
      • Table Global respiratory drugs market 2015-2020 ($ billions)
      • Table Global respiratory drugs market shares by type of disease 2015
    • Global COPD drugs market
      • Table Global COPD drugs market 2015-2020 ($ billions)
      • Table Key drivers and challenges in global COPD drugs market
      • Table Global COPD drugs market by class of drugs 2015
  • Market landscape
    • COPD drugs market in china
      • Table COPD drugs in China in global respiratory drugs market 2015
      • Table COPD drugs market in China 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Segmentation of COPD drugs based on drug class
    • Bronchodilators
    • PDE-4 inhibitors
    • Steroids
    • Combination therapies
    • Other medications
  • Market drivers
    • Increase in prevalence of smoking
    • Rise in healthcare expenditure
      • Table Healthcare spending in China 2004-2014
    • Increase in environmental pollution
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Low diagnosis rate
    • Alternative therapies
    • High cost of therapy
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Rise in awareness programs
    • Increased focus on combination therapies
    • Rise in R&D by global companies
  • Vendor landscape
    • Competitive scenario
    • AstraZeneca
      • Table AstraZeneca: YoY revenue and growth rate of Symbicort in China 2014-2015 ($ millions)
      • Table AstraZeneca: YoY revenue and growth rate of Symbicort in emerging markets 2013-2015 ($ millions)
      • Table AstraZeneca: YoY revenue and growth rate of Pulmicort in China 2014-2015 ($ millions)
      • Table AstraZeneca: YoY revenue and growth rate of Pulmicort in emerging markets 2013-2015 ($ millions)
      • Table AstraZeneca: Key takeaways
    • Boehringer Ingelheim
      • Table Boehringer Ingelheim: Key takeaways
    • GSK
      • Table GSK: YoY revenue and growth rate of Seretide/Advair in international markets 2014-2015 ($ billions)
      • Table GSK: YoY revenue and growth rate of Flixotide/Flovent in international markets 2014-2015 ($ millions)
      • Table GSK: YoY revenue and growth rate of Ventolin in international markets 2014-2015 ($ millions)
      • Table GSK: YoY growth and revenue of Relvar/Breo Ellipta in international markets 2014-2015 ($ millions)
      • Table GSK: Key takeaways
    • Merck
      • Table Merck: Key takeaways
    • Novartis
      • Table Novartis: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report